Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Operating Expenses (2017 - 2025)

UroGen Pharma's Operating Expenses history spans 9 years, with the latest figure at $53.7 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 7.86% year-over-year to $53.7 million; the TTM value through Dec 2025 reached $222.2 million, up 24.62%, while the annual FY2025 figure was $222.2 million, 24.62% up from the prior year.
  • Operating Expenses reached $53.7 million in Q4 2025 per URGN's latest filing, up from $51.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $62.1 million in Q2 2025 to a low of $32.0 million in Q3 2023.
  • Average Operating Expenses over 5 years is $40.5 million, with a median of $36.0 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: dropped 15.19% in 2021, then skyrocketed 38.77% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $34.5 million in 2021, then increased by 4.67% to $36.1 million in 2022, then decreased by 0.71% to $35.9 million in 2023, then surged by 38.77% to $49.8 million in 2024, then rose by 7.86% to $53.7 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Operating Expenses are $53.7 million (Q4 2025), $51.6 million (Q3 2025), and $62.1 million (Q2 2025).